Research demonstrates that inhibition of the AR pathway by enzalutamide can upregulate the HER2 signaling pathway, thereby enabling prostate cancer cells to sustain growth and survival through this compensatory mechanism [51]. Here, ERBB2 is linked to prostate carcinoma.